mirtazapine has been researched along with Sex Disorders in 8 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mirtazapine was administered in the newly developed fast dissolving, orally disintegrating tablet formulation." | 2.71 | Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. ( Agren, H; Bäuml, J; Behnke, K; Martin, S; Ravindran, AV; Søgaard, J; Vester-Blokland, ED, 2003) |
| " Twenty-four men with an intravaginal ejaculation latency time (IELT) less than 1 minute were randomly assigned to paroxetine (20 mg/d) or mirtazapine (30 mg/d) for a period of 6 weeks; half the dosage was given in the first week." | 2.71 | Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine. ( Olivier, B; Waldinger, MD; Zwinderman, AH, 2003) |
| "Anecdotal reports have suggested that the long-term use of selective serotonin reuptake inhibitors (SSRIs) may be associated with significant weight gain, sexual dysfunction, drug interactions, and discontinuation symptoms." | 2.41 | Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. ( Gupta, S; Masand, PS, 2002) |
| " The sexual symptoms resolved gradually after a few days and reappeared upon every dosage increase." | 1.35 | A case of mirtazapine-induced spontaneous orgasms in a female patient. ( Ben-Zion, I; Shalev, H; Shiber, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Masand, PS | 1 |
| Gupta, S | 1 |
| Gupta, RK | 1 |
| Tiller, JW | 1 |
| Burrows, GD | 1 |
| Behnke, K | 1 |
| Søgaard, J | 1 |
| Martin, S | 1 |
| Bäuml, J | 1 |
| Ravindran, AV | 1 |
| Agren, H | 1 |
| Vester-Blokland, ED | 1 |
| Waldinger, MD | 2 |
| Zwinderman, AH | 2 |
| Olivier, B | 2 |
| Schweitzer, DH | 1 |
| Shalev, H | 1 |
| Ben-Zion, I | 1 |
| Shiber, A | 1 |
| Farah, A | 1 |
| Koutouvidis, N | 1 |
| Pratikakis, M | 1 |
| Fotiadou, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of a High Eicosapentaenoic Acid Multinutrient Supplement on Measures of Stress, Anxiety and Depression in Young Adults: a Randomised, Double-blind, Placebo-controlled Trial.[NCT04844034] | 94 participants (Anticipated) | Interventional | 2022-04-19 | Recruiting | |||
| Effects of a Tissue Selective Estrogen Complex (TESC) on Depression and the Neural Reward System in the Perimenopause[NCT03740009] | Phase 4 | 20 participants (Actual) | Interventional | 2019-01-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary outcome measure is functional magnetic resonance imaging (fMRI) data collected during a Monetary Incentive Delay (MID) Task. All participants will complete the fMRI Monetary Incentive Delay (MID) task at baseline and at 3 weeks. During the task, participants need to select the correct response during win and lose conditions by pressing a button on a button box in the MRI. Participant's blood-oxygen-level dependent (BOLD) activation response (A measurement of oxygen level that is released to neurons since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen to perform the tasks.) is measured while they performed the task in MRI scanner." (NCT03740009)
Timeframe: Baseline to 3 weeks
| Intervention | percent signal change (Mean) | |||||
|---|---|---|---|---|---|---|
| Caudate Baseline | Caudate Posttreatment | Nucleus Accumbens Baseline | Nucleus Accumbens Posttreatment | Putamen Baseline | Putamen Posttreatment | |
| Perimenopausal Women, Depressed | .0704 | .0475 | .0623 | .0280 | .0399 | .0408 |
The second primary outcome measure uses the Mood and Anxiety Symptoms Questionnaire - Anhedonic Depression Scale (MASQ-AD) to examine symptom change. All participants will complete the MASQ-AD at each study visit, which measures their current symptoms of depression and anxiety. Scores range from 22 to 110 with lower scores reflecting a better outcome. (NCT03740009)
Timeframe: Baseline, week 2, week 3, week 4 (post treatment)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline Week 1 | Week 2 | Week 3 | Post Treatment Week 4 | |
| Perimenopausal Women, Depressed | 72.1 | 62.4 | 57.2 | 54.5 |
2 reviews available for mirtazapine and Sex Disorders
| Article | Year |
|---|---|
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Dual action antidepressants and some important considerations.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Second-Generation; Cyclohexanols; Cyclopropanes | 2003 |
3 trials available for mirtazapine and Sex Disorders
| Article | Year |
|---|---|
Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorde | 2003 |
Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Confi | 2003 |
The use of mirtazapine in a group of 11 patients following poor compliance to selective serotonin reuptake inhibitor treatment due to sexual dysfunction.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Humans; Male; Mianserin; Mirta | 1999 |
3 other studies available for mirtazapine and Sex Disorders
| Article | Year |
|---|---|
Geometric mean IELT and premature ejaculation: appropriate statistics to avoid overestimation of treatment efficacy.
Topics: Antidepressive Agents; Coitus; Data Interpretation, Statistical; Ejaculation; Fluoxetine; Fluvoxamin | 2008 |
A case of mirtazapine-induced spontaneous orgasms in a female patient.
Topics: Antidepressive Agents, Tricyclic; Anxiety; Depressive Disorder; Female; Hospitals, Psychiatric; Huma | 2009 |
Lack of sexual adverse effects with mirtazapine.
Topics: Adult; Antidepressive Agents, Tricyclic; Female; Humans; Mianserin; Middle Aged; Mirtazapine; Sexual | 1998 |